Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model

Neuropsychopharmacology

Volumn 28, Issue 2, 2003, Pages 235-243

  Keck, Martin E ^a   Welt, Tobias ^a   Müller, Marianne B ^a   Uhr, Manfred ^a   Ohl, Frauke ^a   Wigger, Alexandra ^a   Toschi, Nicola ^a   Holsboer, Florian ^a   Landgraf, Rainer ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Anxiety; Corticotropin releasing hormone; Depression; High anxiety related behavior; Hypothalamic pituitary adrenocorticalsystem; Vasopressin

Indexed keywords

MESSENGER RNA; PAROXETINE; VASOPRESSIN DERIVATIVE;

ANIMAL; ANXIETY DISORDER; ARTICLE; BIOSYNTHESIS; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; HYPOTHALAMUS; MALE; METABOLISM; NEUROSECRETION; RAT; SPECIES DIFFERENCE;

ANIMALS; ANXIETY DISORDERS; DISEASE MODELS, ANIMAL; HYPOTHALAMUS; MALE; NEUROSECRETORY SYSTEMS; PAROXETINE; RATS; RNA, MESSENGER; SPECIES SPECIFICITY; VASOPRESSINS;

EID: 0037311629     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300040     Document Type: Article

References (53)

1. Altemus M, Cizza G, Gold PW (1992). Chronic fluoxetine treatment reduces hypothalamic vasopressin secretion in vitro. Brain Res 593: 311-313.
2. Antoni FA (1993). Vasopressinergic control of pituitary adreno-corticotropin secretion comes of age. Front Neuroendocrinol 14: 76-122.
3. 1a receptors. Neuroendocrinology 62: 135-146.
4. Barberis C, Tribollet M (1996). Vasopressin and oxytocin receptors in the central nervous system. Crit Rev Neurosci 10: 119-154.
5. Bhattacharya SK, Bhttacharya A, Chakrabarti A (1998). Anxiogenic activity of intraventricularly administered arginine-vasopressin in the rat. Biogenic Amines 14: 367-385.
6. Brady LS, Whitfield Jr H, Fox RJ, Gold PW, Herkenham M (1991). Long-term antidepressant administration alters corticotropinreleasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest 87: 831-837.
7. Butterweck V, Winterhoff H, Herkenham M (2001). St John’s Wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Mol Psychiatry 6: 547-564.
8. Connor TJ, Kelliher P, Shen Y, Harkin A, Kelly JP, Leonard BE (2000). Effect of subchronic antidepressant treatments on behavioral, neurochemical, and endocrine changes in the forced-swim test. Pharmacol Biochem Behav 65: 591-597.
9. de Bellis MD, Gold PW, Geracioti Jr TD, Listwak SJ, Kling MA (1993). Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 150: 656-667.
10. de Goeij DCE, Dijkstra H, Tilders FJH (1992). Stress-induced increases in vasopressin and corticotropin-releasing factor expression in hypophysiotrophic paraventricular neurons. Endocrinology 131: 847-853.
11. Ebner K, Wotjak CT, Holsboer F, Landgraf R, Engelmann M (1999). Vasopressin released within the septal brain area during swim stress modulates the behavioural stress response in rats. Eur J Neurosci 11: 997-1002.
12. Faull CM, Charlton JA, Butler TJ, Baylis PH (1993). The effect of acute pharmacological manipulation of central serotonin neurotransmission on osmoregulated secretion of arginine vasopressin in the rat. J Endocrinol 139: 77-87.
13. Geyer MA, Markou A (1995). Animal models of psychiatric disorders. In: Bloom FE, KupferDJ (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York. pp 787-798.
14. Gillies GE, Linton EA, Lowry PJ (1982). Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 299: 355-357.
15. Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B (2002). Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR 149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99: 6370-6375.
16. Hatzinger M, Reul JMHM, Landgraf R, Holsboer F, Neumann I (1996). Combined dexamethasone/CRH test in rats: hypothala-mo-pituitary-adrenocortical system alterations in aging. Neuroendocrinology 64: 349-356.
17. Henniger MSH, Ohl F, Hölter SM, Weissenbacher P, Toschi N, Lörscher P (2000). Unconditioned anxiety and social behaviour in two rat lines selectively bred for high and low anxiety-related behaviour. Behav Brain Res 111: 153-163.
18. Hökfelt T, Broberger C, Xu ZQD, Sergeyev V, Ubink R, Diez M (2000). Neuropeptides—an overview. Neuropharmacology 39: 1337-1356.
19. Holsboer F (2000). The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23: 477-501.
20. Holsboer F, Barden N (1996). Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 17: 187-205.
21. Insel TR, Young LJ (2000). Neuropeptides and the evolution of social behavior. Curr Opin Neurobiol 10: 784-789.
22. Javed A, Kamradt MC, van de Kar LD, Gray TS (1999). d-Fenfluramine induces serotonin-mediated fos expression in corticotropin-releasing factor and oxytocin neurons of the hypothalamus, and serotonin-independent fos expression in enkephalin and neurotensin neurons of the amygdala. Neuroscience 90: 851-858.
23. Keck ME, Hatzinger M, Wotjak CT, Holsboer F, Landgraf R, Neumann ID (2000). Ageing alters intrahypothalamic release patterns of vasopressin and oxytocin in rats. Eur J Neurosci 12: 1487-1494.
24. Keck ME, Holsboer F (2001). Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides 22: 835-844.
25. Keck ME, Welt T, Post A, Müller MB, Toschi N, Wigger A (2001). Neuroendocrine and behavioral effects of repetitive transcranial magnetic stimulation in a psychopathological animal model are suggestive of antidepressant-like effects. Neuropsychopharmacology 24: 337-349.
26. Keck ME, Welt T, Wigger A, Renner U, Engelmann M, Holsboer F (2001). The anxiolytic effect of the CRH1 receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 13: 373-380.
27. Keck ME, Wigger A, Welt T, Müller MB, Gesing A, Reül JMHM (2002). Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. Neuropsychopharmacology 26: 94-105.
28. Kim JK, Summer SN, Wood WM, Schrier RW (2001). Role of glucocorticoid hormones in arginine vasopressin gene regulation. Biochem Biophys Res Commun 289: 1252-1256.
29. Landgraf R, Gerstberger R, Montkowski A, Probst JC, Wotjak CT, Holsboer F (1995). V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities and anxiety-related behavior in rats. J Neurosci 15: 4250-4258.
30. Landgraf R, Wotjak CT, Neumann ID, Engelmann M (1998). Release of vasopressin within the brain contributes to neuroendocrine and behavioral regulation. In: Urban IJA, Burbach JPH, De Wied D (eds). Progress in Brain Research. Elsevier Science B.V.: Amsterdam. pp 201-220.
31. Liebsch G, Linthorst ACE, Neumann ID, Reul JMHM, Holsboer F, Landgraf R (1998). Behavioral, physiological, and neuroendocrine stress responses and differential sensitivity to diazepam in two Wistar rat lines selectively bred for high and low anxiety-related behavior. Neuropsychopharmacology 19: 381-396.
32. Liebsch G, Montkowski A, Holsboer F, Landgraf R (1998). Behavioural profiles of two Wistar rat lines selectively bred for high or low anxiety-related behaviour. Behav Brain Res 94: 301-310.
33. Liebsch G, Wotjak CT, Landgraf R, Engelmann M (1996). Septal vasopressin modulates anxiety-related behaviour in rats. Neurosci Lett 217: 101-104.
34. Lucki I (1997). The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8: 523-532.
35. Ma XM, Aguilera G (1999). Differential regulation of corticotropinreleasing hormone and vasopressin transcription by glucocorticoids. Endocrinology 140: 5642-5650.
36. Müller MB, Landgraf R, Preil J, Sillaber I, Kresse AE, Keck ME(2000). Selective activation of the hypothalamic vasopressinergic system in mice deficient for the corticotropin-releasing hormone receptor 1 is dependent on glucocorticoids. Endocrinology 141: 4262-4269.
37. Nickel T, Sonntag A, Schill J, Zobel AW, Ackl N, Brunnauer A (2003). Clinical and neurobiological findings of tianeptine and paroxetine in major depression. J Clin Psychopharmacol, in press.
38. Ohl F, Toschi N, Wigger A, Henniger MSH, Landgraf R (2001). Dimensions of emotionality in a rat model of innate anxiety. Behav Neurosci 115: 429-436.
39. Purba JS, Hoogendijk WJG, Hofman MA, Swaab DF (1996). Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry 53: 137-143.
40. Raap DK, van de Kar (1999). Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sci 65: 1217-1235.
41. Reul JMHM, Gesing A, Droste S, Stec ISM, Weber A, Bachmann C (2000). The brain mineralocorticoid receptor: greedy for ligand, mysterious in function. Eur J Pharmacol 405: 235-249.
42. Sawchenko PE, Swanson LW, Steinbusch HWM, Verhofstad AAJ (1983). The distribution and cells of origin of the serotonergic inputs to the paraventricular and supraoptic nuclei of the rat. Brain Res 277: 355-360.
43. Stout SC, Owens MJ, Nemeroff CB (2002). Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. J Pharmacol Exp Ther 300: 1085-1092.
44. Tilders FJH, Schmidt ED, de Goeij DCE (1993). Phenotypic plasticity of CRF neurons during stress. Ann NY Acad Sci 697: 39-52.
45. Vacher CM, Frétier P, Crémion C, Calas A, Hardin-Pouzet H (2002). Activation by serotonin and noradrenaline of vasopressin and oxytocin expression in the mouse paraventricular and suproptic nuclei. J Neurosci 22: 1513-1522.
46. 2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci 21: 3572-3579.
47. van Londen L, Goekopp JC, van Kempen GMJ, Frankhuij-zen-Sierevogel AC, Wiegant VM, van der Velde EA (1997). Plasma levels of arginine vasopressin are elevated in patients with major depression. Neuropsychopharmacology 17: 284-292.
48. von Bardeleben U, Holsboer F (1989). Cortisol response to a combined dexamethasone-human corticotropin-releasing hormone (CRH) challenge in patients with depression. J Neuroen-docrinol 1: 485-488.
49. Wotjak CT, Kubota M, Kohl G, Landgraf R (1996a). Release of vasopressin from supraoptic neurons within the rat median eminence in vivo. A combined microdialysis and push-pull perfusion study in the rat. Brain Res 726: 237-241.
50. Wotjak CT, Kubota M, Liebsch G, Montkowski A, Holsboer F, Neumann I (1996). Release of vasopressin within the rat paraventricular nucleus in response to emotional stress: a novel mechanism of regulating adrenocorticotropic hormone secretion? J Neurosci 16: 7725-7732.
51. Zhang Y, Raap DK, Garcia F, Serres F, Ma Q, Battaglia G (2000). Long-term fluoxetine produces behavioral anxiolytic effects without inhibiting neuroendocrine responses to conditioned stress in rats. Brain Res 855: 58-66.
52. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M (2001). Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. J Psychiatr Res 35: 83-94.
53. Zobel AW, Yassouridis A, Frieboes RM, Holsboer F (1999). Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry 156: 949-951.